Ji Yan Biomedical and Taipei Medical University Initiate a Targeted Collaboration on Gamma Delta T Cell in Glioblastoma Preclinical Research

December 2024 — Taipei

Ji Yan Biomedical today announced the initiation of a targeted research collaboration with Taipei Medical University (TMU) to advance preclinical development activities in glioblastoma with its gamma delta T cell (γδT) immunotherapy platform.

This specific collaboration focuses on functional validation, tumor model applications, and translational research related to unmodified γδT cell candidates.

The academic principal investigator for this collaboration is Dr. Tsung-I Hsu, Professor at TMU, an expert in medical neuroscience.

This partnership is part of Ji Yan Biomedical’s broader strategy to engage multiple academic institutions to accelerate the scientific and translational development of its γδT cell programs.

“We are excited to work alongside Taipei Medical University, leveraging their academic strengths to further validate and expand our gamma delta T cell research,” said Dr. Ethan Shen, CEO of Ji Yan Biomedical. “Strategic collaborations like this are essential to advancing the next generation of immunotherapies.”

The collaboration is governed under a mutual confidentiality and intellectual property agreement, and all research will be conducted in compliance with institutional and regulatory standards.

About Ji Yan Biomedical

Ji Yan Biomedical is a biotechnology company developing innovative cellular and exosome-based therapies for oncology, regenerative medicine, and immunology. The company partners with leading academic and clinical institutions to translate pioneering science into next-generation therapeutic solutions.